Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Clovis Oncology Inc (NASDAQ:CLVS)

37.34
Delayed Data
As of 4:00pm ET
 -1.07 / -2.79%
Today’s Change
11.57
Today|||52-Week Range
40.30
+6.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: Rociletinib, Rucaparib and Lucitani. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Other institutional72.59%
Mutual fund holders26.69%
Individual stakeholders16.66%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlVP, Chief Financial & Accounting Officer
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Paul GrossChief Compliance Officer, SVP & General Counsel